EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments

Paul Gulig, Scott Swindle, Mark Fields, Daniel Eisenman iD

Applied Biosafety · 01.12.2024 · 29 (4) · 186-206

DOI: 10.1089/apb.2024.0002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Applied Biosafety, online erschienen am 08.05.2024. Verfasst von Paul Gulig und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Discussion of gene-modified investigational products (IPs) in clinical trials has largely focused on nucleic acid-based vectors, viral vectors, and gene-modified cellular products involving mammalian cells. Use of bacteria and bacteriophages as IPs is resurgent, and discussion of the risks associated with genetic modification of these organisms has become pertinent to the biosafety community.

Methods

This review article summarizes the United States Food and Drug Administration classification for IPs comprising bacteria or bacteriophages and provides an overview of clinical trials conducted to date involving genetically modified bacteria. The risk assessment for bacterial or bacteriophage-based IPs is discussed.

Conclusion

The risk assessment process for bacterial or bacteriophage-based IPs is different from that of gene expression vectors and mammalian cells. Greater consideration must be given to the attenuating mutations affecting virulence, replication competency, antibiotic susceptibility, and persistence in the environment. With the recent growth in clinical trials involving genetically modified bacteria, biosafety professionals and Institutional Biosafety Committees with responsibilities including oversight of clinical trials must become familiar with the associated risk assessment.

Schlagwörter

Stichwörter der Autor:innen

bacteriaclinical trialgene therapygenetically modified organismsphagerisk assessment

Autor:innen und Institutionen

  • Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, USA.
  • Advarra, Columbia, Maryland, USA.
  • Department of Ophthalmology, Yale University, Yale School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Daniel Eisenman

Zitieren

APA

Gulig, P., Swindle, S., Fields, M., & Eisenman, D. (2024). A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments. Applied Biosafety, 29(4), 186-206. https://doi.org/10.1089/apb.2024.0002

Vancouver

Gulig P, Swindle S, Fields M, Eisenman D. A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments. Applied Biosafety. 2024;29(4):186-206. doi:10.1089/apb.2024.0002

BibTeX
@article{Gulig2024,
  author = {Gulig, Paul and Swindle, Scott and Fields, Mark and Eisenman, Daniel},
  title = {A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments},
  journal = {Applied Biosafety},
  year = {2024},
  volume = {29},
  number = {4},
  pages = {186--206},
  doi = {10.1089/apb.2024.0002}
}
Kostenlos starten →